Tuberculosis vaccine research in China

References

• Announcement of the national tuberculosis prevention and control plan (2001–2010). State Council of the People’s Republic of China, General Office: Beijing, China, 2001. Document No. 75.
   Google Scholar
• Zhao FZ, Zhao Y, Liu XQ. Tuberculosis control in China. Tuberculosis2003; 83: 15–20.
   PubMed Web of Science ®Google Scholar
• Wang LD, Liu JJ, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. The Lancet2007; 369: 691–696.
   PubMed Web of Science ®Google Scholar
• Wei YZ, Liu SW, Xia F. Initial research of dendritic cell vaccine against tuberculosis. Med J Wuhan Univ2005; 26: 747–752.
   Google Scholar
• Liu EM, Law HK, Lau YL. Mycobacterium bovis bacillus Calmette–Guerin treated human cord blood monocyte-derived dendritic cells polarize naive T cells into a tolerogenic phenotype in newborns. World J Pediat2010; 6: 132–140.
   PubMed Web of Science ®Google Scholar
• Wang LM, Shi CH, Fan XL, Xue Y, Bai YL, Xu ZK. Expression and immunogenicity of recombinant Mycobacterium bovis bacillus Calmette–Guerin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis. Chin Med J (Engl)2007; 120: 1220–1225.
   PubMed Web of Science ®Google Scholar
• Wang JL, Qie YQ, Zhu BD et al. Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Med Microbiol Immunol (Berl)2009; 198: 5–11.
   PubMed Web of Science ®Google Scholar
• Shen HB, Wang C, Yang EZ et al. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol2010; 54: 435–441.
   PubMed Web of Science ®Google Scholar
• Yang XL, Bao L, Deng YH. A novel recombinant Mycobacterium bovis bacillus Calmette–Guerin strain expressing human granulocyte macrophage colony-stimulating factor and Mycobacterium tuberculosis early secretory antigenic target 6 complex augments Th1 immunity. Acta Biochim Biophys Sin2011; 43: 511–518.
   Google Scholar
• Li Y, Bao L, Zhang HD, Shang ZL, Zhong Q, Li YS. Expression of M. tuberculosis CFP-10/ESAT-6 fusion gene in M. smegmatis and its immunogenicity. Chin J Med Microbiol2006; 26: 1076–1079.
   Google Scholar
• Fan XY, Ma H, Guo J et al. A novel differential expression system for gene modulation in Mycobacteria. Plasmid2009; 61: 39–46.
   PubMed Web of Science ®Google Scholar
• Zhang LX, Wu XQ, Dong EJ. Construction and identification of ESAT6 recombinant BCG vaccine. J Pract Med2009; 25: 517–520.
   Google Scholar
• Fan XF, Wang LM, Lu XY, Tu ZG, Shi CH, Xu ZK. Cloning and expression of the fusion protein of interleukin-2 and ESAT6 in Mycobacterium bovis Bacillus Calmette Guerin strain. Chin Med J (Engl)2005; 118: 762–765.
   PubMed Web of Science ®Google Scholar
• Shi CH, Xu ZK, Zhu DS, Li Y, Bai YL, Xue Y. Screening and construction of recombinant BCG strains expressing the Ag85B–ESAT6 fusion protein. Chin J Tuberculosis Respir Dis2005; 28: 254–257.
   Google Scholar
• Xu Y, Wang B, Chen J et al. Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of Mycobacterium tuberculosis. Scand J Immunol2006; 64: 476–481.
   PubMed Web of Science ®Google Scholar
• Shi CH, Zhang TF, Zhu DS et al. The Immunological response induced by Mycobacterium tuberculosis heat shock protein 16.3 and its synthetic peptide in mice. Chin J Tuberculosis Respir Dis2009; 32: 603–607.
   Google Scholar
• Shi CH, An JZ, Tang XF et al. Immune responses and protective efficacy induced in mice by Mycobacterium tuberculosis MPT64–ESAT-6 fusion protein. J 4th Mil Med Univ2006; 27: 769–771.
   Google Scholar
• Fan AL, Shi CH, Su MQ et al. Immunological properties of Rv1009 domain from Mycobacterium tuberculosis. Chin J Lab Med2007; 31: 1282–1286.
   Google Scholar
• Zhang H, Shi CH, Xue Y, Bai YL, Wang LM, Xu ZK. Immune response and protective efficacy induced by fusion protein ESAT6–CFP10 of M. tuberculosis in mice. Chin J Cell Molec Immunol2006; 22: 443–446.
   Google Scholar
• Xue Y, Bai YL, Gao H, Wang LM, Xu ZK. Immune responses induced by Mycobacterium tuberculosis Rv2450 protein in mice. Chin J Cell Molec Immunol2007; 23: 921–923.
   Google Scholar
• Zhang M, Xu Y, Qie YQ et al. Humoral and cellulr immune responses in mice induced by trehalose-6-phosphate phosphatase from Mycobacterium tuberculosis. J Microbes Infect2006; 1: 144–148.
   Google Scholar
• Wang JL, Qie YQ, Zhang HM et al. PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a novel immunodominant antigen of Mycobacterium tuberculosis induces humoral and cellular immune responses in mice. Microbiol Immunol2008; 52: 224–230.
   PubMed Web of Science ®Google Scholar
• Song NN, Wang BX, Shi DS et al. Dimethyldioctyl ammonium bromide-BCG polysaccharide nucleic acid adjuvant enhanced the immunogenicity of a Mycobacterium tuberculosis subunit vaccine. Chin J Tuberculosis Respir Dis2009; 32: 513–516.
   Google Scholar
• Wang JL, Zhang HM, Wang HH. Analysis of predicted CD8+ T cell epitopes from proteins encoded by the specific RD regions of Mycobacterium tuberculosis for vaccine development and specific diagnosis. Mol Biol Rep2010; 37: 1793–1799.
   PubMed Web of Science ®Google Scholar
• Wu XQ, Yang YR, Zhang JX et al. Humoral Immune Responses against the Mycobacterium tuberculosis 38-Kilodalton, MTB48, and CFP-10/ESAT-6 Antigens in Tuberculosis. Clin Vacc Immunol2010; 17: 372–375.
   PubMedGoogle Scholar
• Li YQ, Zeng JM, Shi JF et al. A Proteome-scale identification of novel antigenic proteins in Mycobacterium tuberculosis toward diagnostic and vaccine development. J Proteome Res2010; 9: 4812–4822.
   PubMed Web of Science ®Google Scholar
• You L, Zhao Y, Gao CH. Construction of Ag85B DNA vaccine for Mycobacterium tuberculosis and its immunogenicities. Chin J Tuberculosis Respir Dis2001; 24: 736–739.
   Google Scholar
• Hu J, Wu XQ, Wang LH, Zheng Y. The construction, immunogenicity and protective efficacy of tuberculosis Ag85B DNA vaccine. Sci Technol Eng2006; 6: 1765–1771.
   Google Scholar
• Shi CH, Wang XW, Zhang H, Xu ZK, Li Y, Yuan LT. Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette–Guerin. Acta Biochim Biophys Sin2007; 39: 290–296.
   Google Scholar
• Zhang H, Shi CH, Wang LM, Xue Y, Bai YL, Xu ZK. Immunogenicity of DNA vaccine expressing ESAT6–CFP10 fusion protein of Mycobacterium tuberculosis. J 4th Mil Med Univ2007; 28: 489–492.
   Google Scholar
• Liu JB, Zhu ZY, Wang HB, Y.X, ZhangCF, ZhangY. Construction and immunoprotection of the TB DNA vaccine expressing Mycobacterium tuberculosis Mtb8.4–38000–Ag85B fusion protein. Immunological J2006;22: 47–50.
   Google Scholar
• Gao HF, Yue Y, Hu LK, Xu W, Xiong SD. A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge. Vaccine2009; 27: 5313–5319.
   PubMed Web of Science ®Google Scholar
• Wang QM, Sun SH, Hu ZL et al. Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scand J Immunol2004; 60: 219–225.
   PubMed Web of Science ®Google Scholar
• Wang QM, Sun SH, Kang L. Construction of ubiquitin-Mycobacterium tuberculosis PMT64 fusion gene DNA vaccine and its cellular immunological efficacy in mice. Acad J 2nd Mil Med Univ2007; 29: 117–121.
   Google Scholar
• Wang QM, Yin M, Zhang JC, Hu JQ, He Y, Sun SH. Ubiquitin and ESAT6 antigen fusion gene DNA vaccine induced stronger cellular immune response in mice. Acad J 2nd Mil Med Univ2007; 28: 261–265.
   Google Scholar
• Wang QM, Kang L, Wang XH. Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis. Microbiol Immunol2009; 53: 384–390.
   PubMed Web of Science ®Google Scholar
• Wang DA, Xu J, Feng YH et al. Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine2010; 28: 3134–3142.
   PubMed Web of Science ®Google Scholar
• Dou J, Tang Q, Zhao FS et al. Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and bacillus Galmette–Guerin. Immunol Invest2008; 37: 113–127.
   PubMed Web of Science ®Google Scholar
• Li JL, Yu FL, Wang YQ et al. Constructing nucleic acid vaccine expressing fusion antigens of Mycobacterium tuberculosis Ag85A and ESAT-6, and interleukin 21 as well as studying its immune effect in mice. Lett Biotech2009; 20: 765–768.
   Google Scholar
• Dou J, Tang Q, Yu FL et al. Investigation of immunogenic effect of the BCG priming and Ag85A–GM-CSF boosting in Balb/c mice model. Immunobiol2010; 215: 133–142.
   PubMed Web of Science ®Google Scholar
• Bao L, Gao L, Bao Y. Immunogenicity of interleukin 12 and DNA vaccine prime-BCG boost against Mycobacterium tuberculosis. Int J Infect Dis2010; 14: e446.
   Web of Science ®Google Scholar
• Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, Zhang JC. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine2004; 22: 3622–3627.
   PubMed Web of Science ®Google Scholar
• Li ZM, Song D, Zhang HY et al. Improved humoral immunity against tuberculosis ESAT-6 antigen by chimeric DNA prime and protein boost strategy. DNA Cell Biol2006; 25: 25–30.
   PubMed Web of Science ®Google Scholar
• Li ZM, Zhang HY, Fan XY et al. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine2006; 24: 4565–4568.
   PubMed Web of Science ®Google Scholar
• Bai Y, Xue Y, Gao H et al. Expression and purification of Mycobacterium tuberculosis ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model. Protein Expr Purif2008; 59: 189–196.
   PubMed Web of Science ®Google Scholar
• Shi C, Yuan S, Zhang H, Zhang T, Wang L, Xu Z. Cell-mediated immune responses and protective efficacy against infection with Mycobacterium tuberculosis induced by hsp65 and hIL-2 fusion protein in mice. Scand J Immunol2009; 69: 140–149.
   PubMed Web of Science ®Google Scholar
• Shi C, Zhang H, Zhang T et al. New alternative vaccine component against Mycobacterium tuberculosis-heat shock protein 16.3 or its T-cell epitope. Scand J Immunol2009; 70: 465–474.
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang BX, Hu LN et al. Fusion protein Ag85B–MPT64190–198–Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine2009; 27: 6179–6185.
   PubMed Web of Science ®Google Scholar
• Li Q, Yu H, Zhang Y et al. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol2011; 73: 568–576.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang C, Zhou ZG et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Dev Immunol2011; 2011: 617892.
   PubMedGoogle Scholar
• Qie YQ, Wang JL, Liu W et al. More vaccine efficacy studies on the recombinant bacille Calmette–Guerin Co-expressing Ag85B, Mpt64190–198 and Mtb8.4. Scand J Immunol2009; 69: 342–350.
   PubMed Web of Science ®Google Scholar
• Deng YH, Bao L, Yang XL. Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein. Microbiol Immunol2011; 55: 798–808.
   PubMed Web of Science ®Google Scholar
• Wang QL, Pan Q, Ma YF et al. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine2009; 27: 6712–6722.
   PubMed Web of Science ®Google Scholar
• Tian X, Cai H, Zhu YX. Protection of mice with a divalent tuberculosis DNA vaccine encoding antigens Ag85B and MPT64. Acta Biochim Biophys Sin (Shanghai)2004; 36: 269–276.
   PubMed Web of Science ®Google Scholar
• Cai H, Tian X, Hu XD et al. Immunogenicity and protective efficacy study using combination of four tuberculosis DNA vaccines. Sci China Ser C-Life Sci2003; 46: 495–498.
   PubMedGoogle Scholar
• Cai H, Tian X, Hu XD, Zhuang YH, Zhu YX. Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis. DNA Cell Biol2004; 23: 450–456.
   PubMed Web of Science ®Google Scholar
• Luo XD, Zhu DY, Chen Q, Jiang Y, Jiang S, Yang CS. A study of the protective effect of the DNA vaccine encoding tubercle antigen 85B with MPT64 in mice challenged with Mycobacterium tuberculosis. Chin J Tuberculosis Respir Dis2004; 27: 611–616.
   Google Scholar
• Luo XD, Zhu DY, Jiang S, Chen Q, Jiang Y. The estimation of protective efficacy of the fusion gene vaccine encoding tubercle antigen 85B and MPT64 in mice challenged with Mycobacterium tuberculosis. Natl Med J Chin2004; 84: 687–691.
   Google Scholar
• Cai H, Hu XD, Yu DH, Li SX, Tian X, Zhu YX. Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice. Vaccine2005; 23: 4167–4174.
   PubMed Web of Science ®Google Scholar
• Cai H, Tian X, Hu XD, Li SX, Yu DH, Zhu YX. Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection. Vaccine2005; 23: 3887–3895.
   PubMed Web of Science ®Google Scholar
• Cai H, Yu DH, Tian X, Zhu YX. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol2005; 24: 605–613.
   PubMed Web of Science ®Google Scholar
• Zhu ZY, Xie Y, Wang HB et al. Protective efficacy of co-immunization of T DNA vaccine pVS84 and plasmid pIL2 equivalent to that of BCG. Chin J Zoonoses2006; 22: 318–321.
   Google Scholar
• Liu JB, Zhu ZY, Wang HB, Xie Y, Zhang CF, Zhang Y. Construction of the eukaryotic expression plasmid pVS85B expressing the protective antigen Ag85B of Mycobacterium tuberculosis and its immunoprotective studies. Curr Immunol2006; 26: 121–126.
   Google Scholar
• Shi CH, Wang XW, Zhang H, Zhang TF, Wang LM, Xu ZK. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis. DNA Cell Biol2008; 27: 199–207.
   PubMed Web of Science ®Google Scholar
• Li M, Yu DH, Cai H. DNA prime-BCG boost vaccination strategy improved the protective efficacy against M-tuberculosis H37Rv in mice. Prog Biochem Biophys2007; 34: 746–753.
   Web of Science ®Google Scholar
• Wang C, Chen ZH, Fu RL et al. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice. Med Microbiol Immunol (Berl)2011; 200: 165–175.
   PubMed Web of Science ®Google Scholar
• Fan XL, Gao Q, Fu RL. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol Res2009; 164: 374–382.
   PubMedGoogle Scholar
• Liu SG, Gong Q, Wang CL et al. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice. Immunol Lett2008; 117: 136–145.
   PubMed Web of Science ®Google Scholar
• Wang LM, Bai YL, Shi CH et al. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice. APMIS2008; 116: 1071–1081.
   PubMed Web of Science ®Google Scholar
• Yao WH, Liu SW, Qu XJ, Xiao SB, Liu Y, Liu JY. Enhanced immune response and protection efficacy of a DNA vaccine constructed by linkage of the Mycobacterium tuberculosis Ag85B-encoding gene with the BVP22-encoding gene. J Med Microbiol2009; 58: 462–468.
   PubMed Web of Science ®Google Scholar
• Chen L, Xu M, Wang ZY et al. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunol Med Microbiol2010; 59: 42–52.
   PubMedGoogle Scholar
• Hu XD, Chen ST, Yu DH, Li SX, Cai H. Immunotherapy with combined DNA vaccines is an effective treatment for M. bovis infection in cattle. Vaccine2009; 27: 1317–1322.
   PubMed Web of Science ®Google Scholar
• Yang XY, Chen QF, Cui XH, Yu Y, Li YP. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. J Infect2010; 60: 320–330.
   PubMed Web of Science ®Google Scholar
• Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to antituberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. Plos One2011; 6: e23826.
   PubMed Web of Science ®Google Scholar
• Yang C, He YL, Zhang L et al. GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine. Int J Tuberc Lung Dis2009; 13: 1360–1366.
   PubMed Web of Science ®Google Scholar
• Shi CH, Zhang H, Wang LM et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis2009; 89: 54–61.
   PubMed Web of Science ®Google Scholar
• Shi XL, Li HW, Zhong S. Study on the role of the chimerichsp70/CD80 DNA vaccine for treating infection of Mycobacterium tuberculosis. Chin J Infect Dis2004; 22: 30–33.
   Google Scholar
• Zhu DY, Jiang S, Luo XD. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine2005; 23: 4619–4624.
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhu DY, Luo XD, Jiang Y, Chen Q. Therapeutic effects of DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Zhonghua Jie He He Hu Xi Za Zhi; 28: 305–309. Chinese.
   PubMedGoogle Scholar
• Liang Y, Wu XQ, Zhang JX. Therapeutic effects of chimeric Ag85A/ESAT-6 DNA vaccines combined with chemotherapy in a mouse model infected with multi-drug resistant Mycobacterium tuberculosis. J Chin Antituberc Assoc2007; 29: 382–385.
   Google Scholar
• Liang Y, Wu XQ, Zhang JX. Therapeutic effects of Ag85A DNA vaccines combined with chemotherapy in a mouse model of MDR Mycobacterium tuberculosis infection. Guangdong Med J2007; 28: 1398–1400.
   Google Scholar
• Liang Y, Wu XQ, Zhang JX et al. The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. Vaccine2008; 26: 4536–4540.
   PubMed Web of Science ®Google Scholar
• Liang Y, Wu X, Zhang J et al. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. Scand J Immunol2011; 74: 42–46.
   PubMed Web of Science ®Google Scholar
• Yu DH, Hu XD, Cai H. Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther2008; 15: 652–659.
   PubMed Web of Science ®Google Scholar
• Wu J, Ma H, Qu Q et al. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice. Vaccine2011; 29: 7624–7630.
   PubMed Web of Science ®Google Scholar